- Home
- YYGH vs CODX Comparison
YYGH vs CODX Comparison
Compare YYGH & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YYGH
- CODX
- Stock Information
- Founded
- YYGH 2010
- CODX 2013
- Country
- YYGH Singapore
- CODX United States
- Employees
- YYGH N/A
- CODX N/A
- Industry
- YYGH
- CODX Medical/Dental Instruments
- Sector
- YYGH
- CODX Health Care
- Exchange
- YYGH NYSE
- CODX Nasdaq
- Market Cap
- YYGH 43.0M
- CODX 39.3M
- IPO Year
- YYGH 2024
- CODX 2017
- Fundamental
- Price
- YYGH $1.74
- CODX $1.06
- Analyst Decision
- YYGH
- CODX Hold
- Analyst Count
- YYGH 0
- CODX 1
- Target Price
- YYGH N/A
- CODX $1.50
- AVG Volume (30 Days)
- YYGH 48.0K
- CODX 77.0K
- Earning Date
- YYGH 11-23-2024
- CODX 11-07-2024
- Dividend Yield
- YYGH N/A
- CODX N/A
- EPS Growth
- YYGH 527.44
- CODX N/A
- EPS
- YYGH 0.04
- CODX N/A
- Revenue
- YYGH $37,372,731.00
- CODX $7,321,012.00
- Revenue This Year
- YYGH N/A
- CODX N/A
- Revenue Next Year
- YYGH N/A
- CODX N/A
- P/E Ratio
- YYGH $43.28
- CODX N/A
- Revenue Growth
- YYGH 55.18
- CODX 57.16
- 52 Week Low
- YYGH $0.72
- CODX $1.00
- 52 Week High
- YYGH $4.70
- CODX $2.23
- Technical
- Relative Strength Index (RSI)
- YYGH N/A
- CODX 30.68
- Support Level
- YYGH N/A
- CODX $1.11
- Resistance Level
- YYGH N/A
- CODX $1.19
- Average True Range (ATR)
- YYGH 0.00
- CODX 0.05
- MACD
- YYGH 0.00
- CODX -0.01
- Stochastic Oscillator
- YYGH 0.00
- CODX 5.11
About YYGH YY GROUP HOLDING LIMITED
YY Group Holding Ltd is a data and technology driven company focused on developing enterprise intelligent labor matching services and smart cleaning services founded in Singapore. It provides enterprise manpower outsourcing and smart cleaning services in Singapore and Malaysia. The group has two operating segment, which is cleaning services segment and manpower outsourcing services, Maximum revenue is generated from cleaning services.
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.